Chemistry:Trimebutine
 | |
| Clinical data | |
|---|---|
| Trade names | Debridat, Recutin, Polybutin, others |
| AHFS/Drugs.com | International Drug Names |
| ATC code | |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C22H29NO5 |
| Molar mass | 387.476 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
  (what is this?) (verify) | |
Trimebutine is a drug with antimuscarinic and weak mu opioid agonist effects.[1] It is used for the treatment of irritable bowel syndrome and other gastrointestinal disorders.
The major product from drug metabolism of trimebutine in human beings is nortrimebutine,[2] which comes from removal of one of the methyl groups attached to the nitrogen atom. Trimebutine exerts its effects in part due to causing a premature activation of phase III of the migrating motor complex in the digestive tract.[3]
Both trimebutine and its metabolite[citation needed] are commercially available.
Brand names
The maleic acid salt of trimebutine is marketed under the trademarks of Antinime, Cineprac, Colospasmyl, Colypan, Crolipsa, Debricol, Debridat, Digedrat, Espabion, Gast Reg, Irritratil, Krisxon, Muttifen, Neotina, Polybutin,[4] Sangalina, Trebutel, Tribudat, Tributina, Trim, Trimeb, Trimedat, and Trimedine.
See also
References
- ↑ "The opioid receptor selectivity for trimebutine in isolated tissues experiments and receptor binding studies". Journal of Pharmacobio-Dynamics 13 (7): 448–53. July 1990. doi:10.1248/bpb1978.13.448. PMID 1963196.
- ↑ "Pharmacological properties of trimebutine and N-monodesmethyltrimebutine". The Journal of Pharmacology and Experimental Therapeutics 289 (3): 1391–7. June 1999. PMID 10336531.
- ↑ "Effectiveness of prokinetic agents against diseases external to the gastrointestinal tract". Journal of Gastroenterology and Hepatology 24 (4): 537–46. April 2009. doi:10.1111/j.1440-1746.2009.05780.x. PMID 19220673. http://onlinelibrary.wiley.com/store/10.1111/j.1440-1746.2009.05780.x/asset/j.1440-1746.2009.05780.x.pdf?v=1&t=hl2d93pj&s=53675e2a2742207be72071a180997b9023ea13ec.
- ↑ "Pharmacokinetic and bioequivalence evaluation of two formulations of 100 mg trimebutine maleate (Recutin and Polybutin) in healthy male volunteers using the LC-MS/MS method". Clinica Chimica Acta; International Journal of Clinical Chemistry 375 (1–2): 69–75. January 2007. doi:10.1016/j.cca.2006.06.006. PMID 16854404.
 |  |
